Your session is about to expire
← Back to Search
Other
ALY688 Ophthalmic Solution for Dry Eye Syndrome (OASIS-1 Trial)
Phase 2 & 3
Waitlist Available
Research Sponsored by Allysta Pharmaceutical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
Summary
This trial is testing ALY688 eye drops in two strengths (0.4% and 1%) to see if they are safe and effective for people with dry eye disease.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Corneal fluorescein staining
Side effects data
From 2015 Phase 4 trial • 157 Patients • NCT020033916%
Ocular hyperaemia
5%
Eye pruritus
2%
Nasopharyngitis
2%
Dry eye
1%
Eye irritation
1%
Blepharal pigmentation
1%
Cataract
1%
Conjunctivitis allergic
1%
Acute tonsillitis
1%
Eyelids pruritus
1%
Pharyngitis
1%
Arthritis
1%
Hypersensitivity
1%
Eye pain
1%
Ocular surface disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
DuoTrav
Beta-blocker
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: ALY688 Ophthalmic Solution Concentration 2Experimental Treatment1 Intervention
Group II: ALY688 Ophthalmic Solution Concentration 1Experimental Treatment1 Intervention
Group III: Vehicle Ophthalmic SolutionPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALY688 Ophthalmic Solution
2021
Completed Phase 3
~930
Find a Location
Who is running the clinical trial?
Allysta PharmaceuticalLead Sponsor
3 Previous Clinical Trials
233 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger